- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Celltrion's COVID-19 Antibody Treatment Moves Into Phase 2/3 Trial
Celltrion moves another step forward in its bid to get a coronavirus disease 2019 (COVID-19) treatment on the market.
After receiving positive results from a phase 1 trial for its coronavirus disease 2019 (COVID-19) monoclonal antibody treatment (CT-P59), Incheon, Republic of Korea–based Celltrion Healthcare has received approval to initiate a phase 2/3 trial.
“Given that COVID-19 represents a significant global threat to life, there is an urgent need to identify treatments that can help stabilize our response to the pandemic. The initiation of the global phase II/III pivotal trial of CT-P59 is an important step forward,” said Sang Joon Lee, PhD, senior executive vice president at Celltrion, in a statement.
The news comes as Celltrion’s infliximab biosimilar (Remsima) is being tested in the phase 2 CATALYST trial to assess its efficacy in treating patients with inflammation linked to COVID-19 during hospitalization.
The phase 2/3 trial will be a global trial evaluating the safety and efficacy of CT-P59 in patients with mild-to-moderate symptoms related to COVID-19.
Celltrion, primarily a biosimilar developer and manufacturer, said it expects to have primary results for the phase 2 portion of the study by the end of 2020.
The company has filed an investigational new drug application for the trial in 6 countries, including the Republic of Korea, the United States, and Spain.
Celltrion said it plans to enroll more than 1000 patients in the multinational trial. Assuming the phase 2/3 trial yields positive results, the company expects to be able to apply for emergency use authorization.
“Celltrion has begun manufacturing the process validation batch of CT-P59 and plans to increase manufacturing capabilities to meet the current global and domestic demand for the anti-COVID-19 monoclonal antibody treatment candidate,” the company said in a statement.
In addition to the phase 2/3 trial, Celltrion has initiated an ongoing in-human global phase 1 trial for CT-P59 in patients with mild cases of COVID-19. The company said it also plans to investigate whether CT-P59 is effective as a preventive treatment for those who are in close contact with patients with COVID-19.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
